ArriVent BioPharma, Inc.
AVBP
$25.22
$0.331.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -269.68% | 2.64% | -42.80% | -1.42% | -43.09% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 263.36% | 198.43% | 299.08% | 296.37% | 276.51% |
| Change in Net Operating Assets | -220.92% | -40.80% | 366.53% | -84.16% | 62.34% |
| Cash from Operations | -265.08% | -8.31% | -5.85% | -121.79% | -10.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -869.86% | -- | -- | -- |
| Cash from Investing | -- | -869.86% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.33% | -80.70% | 1,261.54% | 8,975.00% | 713,869.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.36% | 105.20% | 151.40% | 1,915.00% | 312.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -114.63% | -2,409.66% | 4.01% | 44.32% | 494.57% |